These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 38251353)

  • 1. Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies.
    Lazarevic I; Banko A; Miljanovic D; Cupic M
    Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B.
    Zeng Y; Zhu C; Huang E; Xun Z; Zhang Y; Chen T; Lin C; Fu Y; Wu S; Yang B; Ou Q; Liu C
    Clin Chim Acta; 2024 Jan; 553():117739. PubMed ID: 38145642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
    Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
    Hepatol Commun; 2022 Aug; 6(8):1870-1880. PubMed ID: 35368148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
    Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
    Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection.
    Burm R; Van Houtte F; Verhoye L; Mesalam AA; Ciesek S; Roingeard P; Wedemeyer H; Leroux-Roels G; Meuleman P
    JHEP Rep; 2023 Mar; 5(3):100646. PubMed ID: 36748051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets.
    Colagrossi L; Salpini R; Scutari R; Carioti L; Battisti A; Piermatteo L; Bertoli A; Fabeni L; Minichini C; Trimoulet P; Fleury H; Nebuloso E; De Cristofaro M; Cappiello G; Spanò A; Malagnino V; Mari T; Barlattani A; Iapadre N; Lichtner M; Mastroianni C; Lenci I; Pasquazzi C; De Sanctis GM; Galeota Lanza A; Stanzione M; Stornaiuolo G; Marignani M; Sarmati L; Andreoni M; Angelico M; Ceccherini-Silberstein F; Perno CF; Coppola N; Svicher V
    Viruses; 2018 Jul; 10(7):. PubMed ID: 29987240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
    Moini M; Fung S
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of HBV surface antigen isoforms in the natural history and treatment of HBV infection.
    Rodgers MA; Shah PA; Anderson M; Vallari AS; Gersch J; Mbanya D; Sauleda Oliveras S; Choudhry S; Leary TP; Kuhns MC; Dawson GJ; Cloherty GA; Lau DTY
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 37026760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance.
    Lin X; Zheng Y; Li H; Lu J; Ren S; Liu Y; Wang X; Zheng S; Ma L; Cao Z; Chen X
    Front Immunol; 2022; 13():1028921. PubMed ID: 36211341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma.
    Suzuki Y; Maekawa S; Komatsu N; Sato M; Tatsumi A; Miura M; Matsuda S; Muraoka M; Nakakuki N; Shindo H; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    Hepatol Res; 2019 Jan; 49(1):51-63. PubMed ID: 30350374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan.
    Chen CH; Changchien CS; Lee CM; Tung WC; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN
    Int J Cancer; 2009 Aug; 125(3):621-9. PubMed ID: 19431214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aiming for cure in HBV and HDV infection.
    Petersen J; Thompson AJ; Levrero M
    J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
    Lempp FA; Volz T; Cameroni E; Benigni F; Zhou J; Rosen LE; Noack J; Zatta F; Kaiser H; Bianchi S; Lombardo G; Jaconi S; Vincenzetti L; Imam H; Soriaga LB; Passini N; Belnap DM; Schulze A; Lütgehetmann M; Telenti A; Cathcart AL; Snell G; Purcell LA; Hebner CM; Urban S; Dandri M; Corti D; Schmid MA
    J Hepatol; 2023 Nov; 79(5):1129-1138. PubMed ID: 37459920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult infection with hepatitis B virus PreS variants synergistically promotes hepatocellular carcinoma development in a high-fat diet context by generating abnormal ceramides.
    Liu C; Chen K; Zhao F; Xuan L; Wang Y; Xu C; Wu Z; Wang D; Qu C
    BMC Med; 2022 Sep; 20(1):279. PubMed ID: 36058909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paucity of liver disease in Canadian Inuit with chronic hepatitis B virus, subgenotype B6 infection.
    Minuk GY; Macrury S; Uhanova J; Caouette S; Coleman N; Cummings K; Larke B; Vardy L; Triet Huyn C; Osiowy C
    J Viral Hepat; 2013 Dec; 20(12):890-6. PubMed ID: 24304459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
    Chu CM
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.